A
RGLS

Abingworth’s Regulus Therapeutics RGLS Stock Holding History

Abingworth’s Portfolio RGLS Stock Details RGLS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		– Sell
-2,728
Closed -$1.08M – 20
2016
Q3 		$1.08M Hold
2,728
– – 1.04% 18
2016
Q2 		$943K Hold
2,728
– – 0.99% 18
2016
Q1 		$2.27M Hold
2,728
– – 2.1% 11
2015
Q4 		$2.85M Hold
2,728
– – 1.72% 12
2015
Q3 		$2.14M Hold
2,728
– – 1.25% 12
2015
Q2 		$3.59M Hold
2,728
– – 1.63% 12
2015
Q1 		$5.54M Hold
2,728
– – 2.36% 10
2014
Q4 		$5.25M Hold
2,728
– – 1.49% 11
2014
Q3 		$2.24M Hold
2,728
– – 1.34% 9
2014
Q2 		$2.63M Hold
2,728
– – 1.22% 8
2014
Q1 		$2.94M Buy
+2,728
New +$3.02M 1.62% 10

Other funds holding RGLS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
SDIC
South Dakota Investment Council Sioux Falls, South Dakota $5.24B AUM 22.1% 1-Year Est. Return
Axa
Axa Paris, France $256M AUM 25.01% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
RPAM
Rhenman & Partners Asset Management Stockholm, Sweden $810M AUM 30.2% 1-Year Est. Return

Abingworth's RGLS Position: Q4 2016 in Review

Abingworth sold out of Regulus Therapeutics (RGLS) in Q4 2016, closing a stake of 2,728 shares — an estimated $1.08M sold.

Abingworth first reported a position in RGLS in Q1 2014 and held it in 11 quarters. The position peaked at $5.54M in Q1 2015. 68 funds tracked by Wall St. Rank hold RGLS as of Q4 2016.

  • Abingworth reported no remaining Regulus Therapeutics position as of Q4 2016 after selling out during the quarter.
  • Abingworth sold 2,728 Regulus Therapeutics shares in Q4 2016, an estimated $1.08M.
  • Abingworth first reported a position in Regulus Therapeutics in Q1 2014 and held it in 11 quarters.
  • Abingworth's Regulus Therapeutics position peaked at $5.54M in Q1 2015.
  • 68 funds tracked by Wall St. Rank held Regulus Therapeutics as of Q4 2016.

Based on Abingworth's 13F filing for Q4 2016, filed 14 Feb 2017.